Video

Diarrhea Prophylaxis With Neratinib

Transcript:

Debu Tripathy, MD: This is a big question: Should we be using diarrhea prophylaxis? I think that if you use diarrhea prophylaxis, you are going to have less diarrhea. I have used that for quite some time with my patients, both with pertuzumab as well as with neratinib. However, we have also learned that if you take that approach, some patients will actually have constipation. Another approach that I sometimes use for my patients, depending on whether they’re naturally prone to constipation or diarrhea, is to not take it prophylactically but take it steadily to the first bowel movement, then take a double dose, and then take it every 6 hours. We do tell patients not to take more than 12 2-mg tablets a day. That way, they can stay on top of it. Sometimes we use drugs like Lomotil [atropine/diphenoxylate]. There is a nonrandomized study looking at diarrhea control called the CONTROL study that is testing a variety of other drugs, such as bile-sequestering agents like colestipol, and nonabsorbable steroids have also been tried. It looks like the bile-sequestering agents might be the most effective, at least with the preliminary data that have been presented so far. But we need a little more information and follow-up to solidify those recommendations.

Ruta D. Rao, MD: When starting neratinib, diarrhea prophylaxis should strongly be considered. Based on the CONTROL trial, we can say that loperamide with either budesonide or colestipol, or both, should be used. You can see that the results were significantly improved for the rates of diarrhea compared with the ExteNET trial, in which no prophylaxis was mandated.

Transcript Edited for Clarity

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
Melanie A. Sheen, MD
Kelly E. McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA
Coy Heldermon, MD, PhD
Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.
Dr Tolaney on Considerations for Adjuvant CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer
Icro Meattini, ​MD, an associate professor in the Department of Clinical and Experimental Biomedical Sciences at the University of Florence; as well as a clinical oncologist in the Radiation Oncology Unit in the Oncology Department and head of the Breast Unit and Breast Cancer Multidisciplinary Team at Florence University Hospital
Angela Jain, MD
5 experts are featured in this series